By DermaSensorLearning Objectives
- Understand what DermaSensor does and where it fits in the care pathway
- Understand why point-of-care skin-cancer detection matters
- Evaluate the device as a decision aid rather than a diagnosis
What Is DermaSensor?
DermaSensor makes a handheld device that helps primary-care physicians assess skin lesions for cancer at the point of care. The clinician places the device on a suspicious lesion; it shines light into the skin and uses elastic-scattering spectroscopy together with an AI algorithm to return an immediate result — essentially "investigate further" versus "monitor." It covers all three common skin cancers: melanoma, basal cell carcinoma, and squamous cell carcinoma. In January 2024 it became the first FDA-cleared AI device for skin-cancer detection in primary care.
Why this matters: most skin checks begin with a generalist, not a dermatologist, and generalists are understandably cautious — some concerning lesions get missed, and many benign ones get referred unnecessarily. A point-of-care tool that helps decide when to refer can catch cancers earlier and reduce needless referrals. The essential framing is that DermaSensor is a decision aid, not a diagnosis: it flags lesions that merit specialist attention, and its value depends on appropriate use and reliable follow-up rather than on replacing dermatology. Used well, it strengthens the first, most common step in the skin-cancer pathway.
💡Key Concept
Point-of-care decision aid: DermaSensor gives a primary-care clinician an immediate, objective signal about a lesion's cancer risk, supporting the referral decision at the moment of the visit — where most skin-cancer pathways actually begin.
⚠️Warning
It supports referral, it does not diagnose. A result guides whether to refer or monitor; it is not a definitive diagnosis. Clinical judgment and appropriate follow-up remain essential, and a negative result does not rule out disease on its own.
🎯Tip
Visit DermaSensor: dermasensor.com — used in primary-care and general-practice settings.
Pricing
DermaSensor is offered to clinics and practices on a subscription model tied to the device rather than published per-use pricing.
- Handheld lesion assessment
- All three common skin cancers
- Immediate point-of-care result
- Multi-site deployment
- Primary-care integration
- Referral-workflow support
Core Features
Handheld Spectroscopy Plus AI
Uses elastic-scattering spectroscopy and an AI algorithm to assess a lesion's cancer risk in seconds at the point of care.
Coverage of Three Common Skin Cancers
Evaluates for melanoma, basal cell carcinoma, and squamous cell carcinoma — the cancers a primary-care clinician most needs help triaging.
Immediate Referral Guidance
Returns a clear "investigate further" or "monitor" signal to support the referral decision during the visit.
Built for Primary Care
Designed for generalists rather than dermatologists, targeting the first and most common step in the skin-cancer pathway.
Strengths
- First FDA-cleared AI skin-cancer device for primary care — a category first
- Point-of-care and immediate — supports the referral decision in the visit
- Covers the three common skin cancers — the ones generalists most need help with
- Extends specialist reach — helps where dermatologists are not present
- Simple workflow — a handheld device with a clear output
Limitations and Considerations
- A decision aid, not a diagnosis — it guides referral, not treatment
- Negative results are not definitive — clinical judgment still applies
- Appropriate use matters — value depends on correct application and follow-up
- Primary-care scope — designed for triage, not specialist evaluation
- Adoption and training — clinicians must integrate it into their workflow
Best Use Cases
| Use Case | Why DermaSensor Fits | Caveat |
|---|---|---|
| Primary-care skin checks | Objective signal to guide referral | Not a definitive diagnosis |
| Reducing unnecessary referrals | Helps distinguish concerning lesions | Clinical judgment still applies |
| Earlier cancer detection | Catches lesions that might be missed | Follow-up is essential |
| Settings without dermatology | Extends triage where specialists are scarce | Designed for primary-care use |
Key Takeaways
- DermaSensor is the first FDA-cleared AI skin-cancer detection device for primary care
- It uses handheld spectroscopy plus AI to assess lesions for all three common skin cancers and guide referral decisions
- It strengthens the first, most common step in the skin-cancer pathway, where generalists — not dermatologists — see patients first
- It is a decision aid, not a diagnosis: results guide referral, and follow-up and clinical judgment remain essential
- It is best for helping primary-care clinicians decide when to refer, catching cancers earlier while reducing unnecessary referrals
